These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 28870843)

  • 1. Phosphatidylserine: A cancer cell targeting biomarker.
    Sharma B; Kanwar SS
    Semin Cancer Biol; 2018 Oct; 52(Pt 1):17-25. PubMed ID: 28870843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of lipid-phosphatidylserine (PS) as the target of unbiasedly selected cancer specific peptide-peptoid hybrid PPS1.
    Desai TJ; Toombs JE; Minna JD; Brekken RA; Udugamasooriya DG
    Oncotarget; 2016 May; 7(21):30678-90. PubMed ID: 27120792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variation in human cancer cell external phosphatidylserine is regulated by flippase activity and intracellular calcium.
    Vallabhapurapu SD; Blanco VM; Sulaiman MK; Vallabhapurapu SL; Chu Z; Franco RS; Qi X
    Oncotarget; 2015 Oct; 6(33):34375-88. PubMed ID: 26462157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of cancer cells using SapC-DOPS nanovesicles.
    Davis HW; Hussain N; Qi X
    Mol Cancer; 2016 May; 15(1):33. PubMed ID: 27160923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SapC-DOPS - a Phosphatidylserine-targeted Nanovesicle for selective Cancer therapy.
    N'Guessan KF; Patel PH; Qi X
    Cell Commun Signal; 2020 Jan; 18(1):6. PubMed ID: 31918715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting and cytotoxicity of SapC-DOPS nanovesicles in pancreatic cancer.
    Chu Z; Abu-Baker S; Palascak MB; Ahmad SA; Franco RS; Qi X
    PLoS One; 2013; 8(10):e75507. PubMed ID: 24124494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphatidylserine: The Unique Dual-Role Biomarker for Cancer Imaging and Therapy.
    Kaynak A; Davis HW; Kogan AB; Lee JH; Narmoneva DA; Qi X
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SapC-DOPS nanovesicles as targeted therapy for lung cancer.
    Zhao S; Chu Z; Blanco VM; Nie Y; Hou Y; Qi X
    Mol Cancer Ther; 2015 Feb; 14(2):491-8. PubMed ID: 25670331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer-selective targeting and cytotoxicity by liposomal-coupled lysosomal saposin C protein.
    Qi X; Chu Z; Mahller YY; Stringer KF; Witte DP; Cripe TP
    Clin Cancer Res; 2009 Sep; 15(18):5840-51. PubMed ID: 19737950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comprehensive lipid binding and activity validation of a cancer-specific peptide-peptoid hybrid PPS1.
    Desai TJ; Udugamasooriya DG
    Biochem Biophys Res Commun; 2017 Apr; 486(2):545-550. PubMed ID: 28322795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L-methionase: a therapeutic enzyme to treat malignancies.
    Sharma B; Singh S; Kanwar SS
    Biomed Res Int; 2014; 2014():506287. PubMed ID: 25250324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic delivery of SapC-DOPS has antiangiogenic and antitumor effects against glioblastoma.
    Wojton J; Chu Z; Mathsyaraja H; Meisen WH; Denton N; Kwon CH; Chow LM; Palascak M; Franco R; Bourdeau T; Thornton S; Ostrowski MC; Kaur B; Qi X
    Mol Ther; 2013 Aug; 21(8):1517-25. PubMed ID: 23732993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphatidylserine-selective targeting and anticancer effects of SapC-DOPS nanovesicles on brain tumors.
    Blanco VM; Chu Z; Vallabhapurapu SD; Sulaiman MK; Kendler A; Rixe O; Warnick RE; Franco RS; Qi X
    Oncotarget; 2014 Aug; 5(16):7105-18. PubMed ID: 25051370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting phosphatidylserine for Cancer therapy: prospects and challenges.
    Chang W; Fa H; Xiao D; Wang J
    Theranostics; 2020; 10(20):9214-9229. PubMed ID: 32802188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SapC-DOPS nanovesicles induce Smac- and Bax-dependent apoptosis through mitochondrial activation in neuroblastomas.
    Sulaiman MK; Chu Z; Blanco VM; Vallabhapurapu SD; Franco RS; Qi X
    Mol Cancer; 2015 Apr; 14():78. PubMed ID: 25889084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biotherapy of Brain Tumors with Phosphatidylserine-Targeted Radioiodinated SapC-DOPS Nanovesicles.
    Davis HW; Vallabhapurapu SD; Chu Z; Wyder MA; Greis KD; Fannin V; Sun Y; Desai PB; Pak KY; Gray BD; Qi X
    Cells; 2020 Aug; 9(9):. PubMed ID: 32854321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting phosphatidylserine in anti-cancer therapy.
    Kenis H; Reutelingsperger C
    Curr Pharm Des; 2009; 15(23):2719-23. PubMed ID: 19689342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surface expression of phosphatidylserine on macrophages is required for phagocytosis of apoptotic thymocytes.
    Callahan MK; Williamson P; Schlegel RA
    Cell Death Differ; 2000 Jul; 7(7):645-53. PubMed ID: 10889509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gla-domain mediated targeting of externalized phosphatidylserine for intracellular delivery.
    Hardy J; Bauzon M; Chan CKF; Makela AV; Kanada M; Schneider D; Blankenberg F; Contag CH; Hermiston T
    FASEB J; 2023 Aug; 37(8):e23113. PubMed ID: 37486772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melanoma cell surface-expressed phosphatidylserine as a therapeutic target for cationic anticancer peptide, temporin-1CEa.
    Wang C; Chen YW; Zhang L; Gong XG; Zhou Y; Shang DJ
    J Drug Target; 2016; 24(6):548-56. PubMed ID: 26596643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.